Value
9.0/10data confidence 33%| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
- ▸Attractively valued
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Enliven Therapeutics is a pre-revenue biotech with 30.8% upside to the analyst target and strong momentum, but quality is far below the floor, it burns cash, and its pipeline depends on one drug.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
| Pillar | Expectation | Trend |
|---|---|---|
The pipeline depends on ELVN-001 and a single supplier, Pharmaron, so one failure would hit the company hard. Bear case | A second program advances to the clinic over 12 months. | ↑Improving |
| CounterThe lead drug may be strong enough to carry the company alone. | ||
Upside of 30.8% to the $64.67 analyst target against 15.0% downside gives a reward-to-risk ratio of 2.06. Estimated upside | Price closes part of the gap to the $64.67 target over 12 months. | →Stable |
| CounterBiotech targets depend on trial outcomes and can be cut sharply on one data release. | ||
Quality scores 1.6, below the 4.0 floor, with negative free cash flow and no competitive moat. Quality breakdown | Quality rises above 3.0 as spending is funded without dilution. | →Stable |
| CounterA pre-revenue biotech is expected to burn cash, so a low quality score says little about pipeline value. | ||
Momentum scores 6.7 with RSI of 79 and rising on-balance volume, while 18% of shares are sold short. Momentum breakdown | Price holds above the 200-day average and RSI falls back below 70. | Tripped↓Deteriorating |
| CounterAn RSI near 80 with 89% implied volatility makes a sharp pullback likely. | ||
Insiders sold $2.23M across 13 sales over 90 days, though institutions are accumulating. Insider breakdown | Insider selling falls below $500K over 90 days. | →Stable |
| CounterSales are only 0.061% of market cap and may be routine. | ||
CounterThe lead drug may be strong enough to carry the company alone.
CounterBiotech targets depend on trial outcomes and can be cut sharply on one data release.
CounterA pre-revenue biotech is expected to burn cash, so a low quality score says little about pipeline value.
CounterAn RSI near 80 with 89% implied volatility makes a sharp pullback likely.
CounterSales are only 0.061% of market cap and may be routine.
| Component | Sub-score |
|---|---|
| Analyst target | 9.0 |
| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Current ratio | 5.0 |
| FCF quality | 0.0 |
| Moat | 4.8 |
| Piotroski F | 4.4 |
| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 0.9 |
| OBV | 10.0 |
| MA position | 6.0 |
| Volume | 1.5 |
| Component | Sub-score |
|---|---|
| Analyst rating | 8.4 |
| Price target | 9.7 |
| erm sentiment | 4.7 |
| Component | Sub-score |
|---|---|
| materiality | 4.5 |
| insider conviction | 2.0 |
| holder change | 8.2 |
| notable moves | 7.0 |
| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 6.6 |
| growth rank | 5.0 |
| Component | Sub-score |
|---|---|
| bollinger | 5.1 |
| support resistance | 5.0 |
| 52w position | 4.9 |
| Component | Sub-score |
|---|---|
| short interest | 1.5 |
| days to cover | 3.6 |
| volatility | 0.0 |
| put call | 10.0 |
| implied vol | 3.5 |
| beta | 10.0 |
| debt equity | 10.0 |
| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 3.3 |
| earnings timing | 5.0 |
| surprise avg | 1.7 |
Quality below minimum threshold.
L1:HARD_BLOCK:QUALITY_FLOORnone
SetupRange Bound — RSI 54 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
The SELL_IF_HOLDING verdict reflects clean gate clearance against Value at 9.0 and asymmetric R:R of 3.22.
The strongest dimensions are Value at 9.0, Sentiment at 7.8, and Peer rank at 6.5; the weakest are Quality at 1.6, Catalyst at 3.8, and Momentum at 4.8. The V9 engine cleared all gates with 1 warning, producing an asymmetric reward-to-risk of 3.22 and an engine sizing output of AVOID.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
Trip ifUpside to the analyst target falls below 10% from the current 30.8%.
Trip ifQuality score rises above 3.0 from the current 1.6.
Trip ifA second program enters clinical trials, taking pipeline programs in the clinic to at least 2.
Trip ifRSI falls below 60 from the current 79 while price stays above the 200-day average.
Trip ifNet insider selling exceeds $10M over 90 days.